CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies

Genetic redirection of T lymphocytes with chimeric antigen receptors (CARs) has soared from treating cancers preclinically to FDA approval for hematologic malignancies and commercial-grade production scale in under 30 years. To date, solid tumors are less susceptible to CAR therapies and instead hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Knochelmann, Hannah M., Smith, Aubrey S., Dwyer, Connor J., Wyatt, Megan M., Mehrotra, Shikhar, Paulos, Chrystal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094980/
https://www.ncbi.nlm.nih.gov/pubmed/30140266
http://dx.doi.org/10.3389/fimmu.2018.01740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094980/
https://www.ncbi.nlm.nih.gov/pubmed/30140266
http://dx.doi.org/10.3389/fimmu.2018.01740

Ejemplares similares